Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : biotech fireworks -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (369)	11/4/2002 12:53:24 PM
From: Jibacoa	Read Replies (1) \| Respond to of 7424

ORCH Has been up more than 15% today (now up only 13.76% <g>)and volume is over 630K (about 3.6x its daily average)it is due to release its 3rdQ results before the market opens on Thursday. siliconinvestor.com Bernard

To: Mike McFarland who wrote (369)	11/4/2002 1:17:13 PM
From: Jibacoa	Respond to of 7424

It has been responding to the data presented at the ASTRO meeting last month, which provided good news for prostate cancer patients.<g> According to the company,"men diagnosed with low-, intermediate or high-risk cancers can now look to TheraSeed as the primary product to provide an exceptional cure rate, as well as a high quality of life with minimal side effects". They said "the data is particularly significant as it is the first 10-year study to quantify the overwhelming success of brachytherapy for aggressive, high-risk cancer. We now have data to support the effectiveness of TheraSeed in men with PSAs greater than 10." "The data is extremely important since the vast majority of patients treated in this study would be considered categorically incurable using any other treatment method, namely radical prostatectomy, external beam radiation alone, with or without hormones, or external beam coupled with any other radioactive isotope. Yet 79 percent of these patients remained completely free of cancer without the use of hormonal therapy or chemotherapy." The shares have been trading below book and with a PE of less than 13.<g>There is no LTD with a CR above 31 Bernard